BPC-157 has the largest preclinical literature of any research peptide in this database: over 500 indexed publications spanning 30 years. It also has one of the smallest human evidence bases: fewer than 30 people have been studied in published trials. That gap defines everything about this compound.
The preclinical data is not in dispute. BPC-157 accelerates healing in animal models of tendon injury, gastric ulcers, muscle damage, burns, surgical wounds, and colonic anastomosis. The mechanism is well-characterized: VEGFR2-driven angiogenesis, Akt/eNOS signaling, and NO system modulation create a molecular explanation for the observed tissue repair effects. A 2025 systematic review in the American Journal of Sports Medicine confirmed the consistency of the preclinical findings across 36 studies.
What is in dispute, or should be, is whether any of this translates to humans. The answer, as of April 2026, is that we do not know.
A Phase 2 trial for inflammatory bowel disease was registered in Croatia in 2015. It enrolled 42 volunteers. The results were never published in a peer-reviewed journal. This is the single largest human exposure to BPC-157 on record, and the data is not available for independent review.
In 2025, Lee and Burgess published a pilot study of intravenous BPC-157 in two healthy adults at doses up to 20 mg. No adverse events were reported. Plasma BPC-157 returned to baseline within 24 hours. This is the complete human pharmacokinetic dataset: two people, a single IV infusion each.
A 2024 pilot study treated 12 women with interstitial cystitis via intravesical injection. All 12 reported symptom improvement. No placebo control was used. The publication venue was Alternative Therapies in Health and Medicine, not a top-tier journal.
That is the full human evidence base. No randomized controlled trials. No dose-finding studies. No pharmacokinetic data for subcutaneous or oral routes, which are the routes people actually use.
In 2023, the FDA placed BPC-157 on the Category 2 bulk drug substance list, meaning it cannot be commercially compounded for human use in the United States.
The Category 2 designation reflects the FDA's assessment that there is insufficient evidence to determine whether BPC-157 would cause harm to humans. This is not a ban on the compound itself. It is a prohibition on pharmacies compounding it for patients. BPC-157 remains legally available as a "research chemical" from unregulated vendors, a classification that requires no purity standards, no quality testing, and no regulatory oversight.
BPC-157 is not on the WADA Prohibited List as of 2026. Athletes are not prohibited from using it, though the lack of human safety data and the unregulated sourcing should give anyone pause.
Most research peptides with weak human evidence also have weak preclinical evidence. BPC-157 is the rare exception: the preclinical literature is genuinely extensive, internally consistent, and mechanistically detailed. The Zagreb research group has published across dozens of injury models over three decades. The VEGFR2-Akt-eNOS pathway provides a coherent molecular explanation that aligns with the observed effects.
The question is not whether BPC-157 does something interesting in animal models. It clearly does. The question is why, after 30 years and 500 papers, no pharmaceutical company, no university, and no government agency has conducted a properly designed human efficacy trial. The cancelled Phase 2 in Croatia makes this question sharper, not softer.
BPC-157 is the most researched and least validated peptide in this database. The preclinical foundation is stronger than almost any other compound we review. The human evidence foundation is weaker than almost any other compound we review. Both of these things are true simultaneously, and anyone who tells you only one of them is not being honest with you.
Read the complete BPC-157 evidence profile, including all use cases, mechanism of action, dosing data, and safety analysis. The full profile is free, no subscription required.
For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use